Polynucleotides
Polynucleotides and menopausal skin: what is realistic?
Menopause can coincide with drier, thinner-feeling skin and changes in texture. Polynucleotides may support selected skin-quality concerns, but they are not a treatment for menopause and expectations should remain measured.
Why skin may feel different around menopause
During perimenopause and after menopause, hormonal change can coincide with skin becoming drier, thinner or less elastic. Fine lines and slower recovery from irritation may become more noticeable. The experience varies considerably, however, and age, sun exposure, smoking, skincare, health conditions and medicines can all affect the skin too.
It is therefore unhelpful to label every new concern as hormonal. Persistent itching, a rash, sudden colour change, a new lesion or rapidly changing skin needs appropriate medical assessment. An aesthetic consultation should begin by clarifying what has changed and whether an injectable treatment is relevant at all.
Where polynucleotides may fit
Polynucleotides are injectable chains of purified DNA fragments used with the aim of supporting skin quality. They do not replace lost facial volume in the way a traditional dermal filler may, and they are not intended to treat hot flushes, sleep disturbance or other menopausal symptoms.
For a suitable person, they may be discussed when the main concern is fine, crepey texture, dryness, reduced elasticity or subtle fine lines. The aim is gradual, modest improvement rather than lifting the face or reversing skin ageing. Basic measures such as daily broad-spectrum sun protection, a gentle cleanser and an appropriate moisturiser remain important whether or not treatment is chosen.
What the research can—and cannot—tell us
Recent clinical studies have reported changes in wrinkle- and texture-related measures after facial polynucleotide treatment. One 2026 prospective split-face study followed 40 adults receiving three sessions and found improvement from baseline in several short-term skin-quality measures. It also showed that technique can influence discomfort and visible injection-site reactions.
That does not prove a specific benefit for menopausal skin. Many studies are small, use different products and methods, and include mixed or younger populations rather than people selected because of menopause-related concerns. Longer-term comparative evidence is limited. Polynucleotides should therefore be presented as one possible skin-quality option, not as a hormone treatment, a substitute for menopause care or a guaranteed way to rebuild collagen.
A course should still be individual
A clinician may recommend a short initial course followed by review, but the product, area, spacing and number of sessions should not be automatic. The decision depends on skin condition, anatomy, previous procedures, tolerance, budget and what would count as a worthwhile change for you.
Progress is usually judged over weeks using the same lighting and camera position. If there is little meaningful benefit, the plan should be reconsidered rather than continued by default. Sometimes skincare, a dermatology or menopause review, another procedure, or no injectable treatment is more appropriate.
Downtime and possible adverse effects
Small raised bumps, redness, tenderness, swelling and bruising can occur at injection points. Delicate areas may look more swollen, and the reactions may be noticeable for several days, so appointments should be planned around work, travel and important events. Infection, an inflammatory reaction or another unexpected complication is less common but possible with any injectable procedure.
Follow the aftercare advice provided. Contact the clinic promptly if pain, swelling, skin colour change or another symptom is severe, worsening or unexpected; do not wait for a routine review when something does not feel right.
Who needs particular care?
Treatment may need to be avoided or postponed during pregnancy or breastfeeding, with active infection or inflammation, or when allergies, autoimmune or other medical conditions, medicines or previous reactions require further assessment. The ingredients and contraindications of the exact product must be checked; fish allergy should be discussed because some products are derived from highly purified salmon or trout DNA.
A face-to-face consultation is essential to examine the skin, review health and medicines, discuss alternatives and agree realistic goals. Menopausal skin is not one skin type, so suitability should be decided for the individual rather than from age or hormone status alone.